US 2025/0145694 A1 · RECOMBINANT ANTIBODY OF ANTI-HUMAN CARDIAC TROPONIN I

Abstract

Provided are an isolated binding protein including an antigen binding domain of cardiac troponin I (cTnI), as well as a preparation and uses of the binding protein. The antigen binding domain includes at least one complementary determining region selected from the amino acid sequences defined herein; or the antigen-binding domain has at least 80% sequence identity with the complementary determining regions of said amino acid sequences and has an affinity for cardiac troponin I of KD≤3.33×10−8 mo/L. The binding protein may be used in the field of cTnI protein detection.

An isolated binding protein comprising an antigen-binding domain, wherein the antigen-binding domain comprises at least one complementary determining region selected from the following amino acid sequences, or the antigen-binding domain has at least 80% sequence identity with the complementary determining regions of the following amino acid sequences and has an affinity for cardiac troponin I of KD≤3.33×10−8 mo/L:

a complementary determining region CDR-VH1 of G-F-T-X1-S-N-Y-A-M-S, where X1 is Y or F;
a complementary determining region CDR-VH2 of I-S-X1-G-G-S-Y-S-X2-Y-P-D-S-V-K, where X1 is S or T, and X2 is Y or F;
a complementary determining region CDR-VH3 of A-R-X1-D-N-Y-X2-G-S-X3-F-M-D-Y, where X1 is R or K, X2 is Y, Por F, and X3 is T or S;
a complementary determining region CDR-VL1 of R-A-S-Q-X1-I-T-X2-Y-L-N, where X1 is D or E, and X2 is N or Q;
a complementary determining region CDR-VL2 of I-Y-Y-X1-S-R-X2-H-S-G-V-S, where X1 is T or S, and X2 is I or L;
and
a complementary determining region CDR-VL3 of Q-Q-G-X1-T-X2-P-L-T, where X1 is N or H, and X2 is I or L,
preferably,
in the complementary determining region CDR-VH2, X1 is S;
in the complementary determining region CDR-VH3, X1 is R;
in the complementary determining region CDR-VL1, X2 is N;
and
in the complementary determining region CDR-VL2, X1 is T,
preferably, in the complementary determining region CDR-VH1, X1 is Y;
preferably, in the complementary determining region CDR-VH1, X1 is F;
preferably, in the complementary determining region CDR-VH2, X2 is Y;
preferably, in the complementary determining region CDR-VH2, X2 is F;
preferably, in the complementary determining region CDR-VH3, X2 is Y, and X3 is T;
preferably, in the complementary determining region CDR-VH3, X2 is P, and X3 is T;
preferably, in the complementary determining region CDR-VH3, X2 is F, and X3 is T;
preferably, in the complementary determining region CDR-VH3, X2 is Y, and X3 is S;
preferably, in the complementary determining region CDR-VH3, X2 is P, and X3 is S;
preferably, in the complementary determining region CDR-VH3, X2 is F, and X3 is S;
preferably, in the complementary determining region CDR-VL1, X1 is D;
preferably, in the complementary determining region CDR-VL1, X1 is E;
preferably, in the complementary determining region CDR-VL2, X2 is I;
preferably, in the complementary determining region CDR-VL2, X2 is L;
preferably, in the complementary determining region CDR-VL3, X1 is N, and X2 is I;
preferably, in the complementary determining region CDR-VL3, X1 is H, and X2 is I;
preferably, in the complementary determining region CDR-VL3, X1 is N, and X2 is L;
preferably, in the complementary determining region CDR-VL3, X1 is H, and X2 is L;
and
preferably, a mutation site of each of the complementary determining regions is selected from anv one of the following mutation combinations:
CDR-
CDR-
CDR-
CDR-
CDR-
CDR-
VH1
VH2
VH3
VL1
VL2
VL3
Site
X1
X2
X2/X3
X1
X2
X1/X2
Mutation combination 1
Y
Y
Y/T
D
I
N/I
Mutation combination 2
F
F
Y/S
E
L
H/L
Mutation combination 3
Y
F
P/T
E
I
N/I
Mutation combination 4
F
Y
P/S
D
L
H/L
Mutation combination 5
Y
Y
F/T
E
L
N/L
Mutation combination 6
F
F
F/S
E
I
H/L
Mutation combination 7
Y
F
Y/S
D
L
N/I
Mutation combination 8
F
Y
F/T
E
I
H/I
Mutation combination 9
Y
Y
F/S
E
I
H/I
Mutation combination 10
F
F
Y/T
D
L
N/L
Mutation combination 11
Y
F
Y/S
D
I
H/L
Mutation combination 12
F
Y
Y/T
D
L
N/I
Mutation combination 13
Y
Y
P/T
E
L
H/L
Mutation combination 14
F
F
P/S
E
I
N/I
Mutation combination 15
Y
F
F/T
D
L
H/I
Mutation combination 16
F
Y
F/S
E
I
N/L
Mutation combination 17
Y
Y
Y/T
D
I
N/I
Mutation combination 18
F
F
Y/S
D
L
H/I
Mutation combination 19
Y
F
P/S
E
I
N/L
Mutation combination 20
F
Y
F/T
E
L
H/L
Mutation combination 21
Y
Y
F/S
D
L
N/L
Mutation combination 22
F
F
Y/T
D
I
H/L
Mutation combination 23
Y
F
Y/S
D
I
H/I
Mutation combination 24
F
Y
P/T
E
I
H/I
Mutation combination 25
Y
Y
F/T
E
I
H/I
Mutation combination 26
F
F
F/S
D
L
N/L
Mutation combination 27
Y
F
Y/T
E
I
H/L
Mutation combination 28
F
Y
Y/S
D
L
N/I
Mutation combination 29
Y
Y
P/T
D
L
H/L
Mutation combination 30
F
F
F/S
E
I
N/I
Mutation combination 31
Y
F
F/S
E
L
H/I
Mutation combination 32
F
Y
Y/T
D
I
N/L
Mutation combination 33
Y
Y
Y/S
D
I
N/I
Mutation combination 34
F
F
P/T
D
L
H/I
Mutation combination 35
Y
F
P/S
D
I
N/I
Mutation combination 36
F
Y
F/T
D
L
H/L
Mutation combination 37
Y
Y
Y/T
E
I
N/L
Mutation combination 38
F
F
Y/S
D
L
H/L
Mutation combination 39
Y
F
P/T
D
L
N/I
Mutation combination 40
F
Y
P/S
D
I
H/I
Mutation combination 41
Y
Y
F/T
E
I
N/L
Mutation combination 42
F
F
F/S
E
L
N/L
Mutation combination 43
Y
F
Y/S
E
I
H/I
Mutation combination 44
F
Y
P/T
D
L
N/I
Mutation combination 45
Y
Y
P/S
D
L
H/L
Mutation combination 46
F
F
F/T
E
I
N/I
Mutation combination 47
Y
F
Y/T
E
L
H/L
Mutation combination 48
F
Y
P/S
D
I
N/L
Mutation combination 49
Y
Y
P/T
E
I
N/I.

392 more elements

Recombinant antibody of anti-human cardiac troponin i

Life of this patent

Recombinant antibody of anti-human cardiac troponin i

Life of this patent

Abstract

Claims20